Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03335280 · ClinicalTrials.gov registry record
68Ga-citrate PET/MR Imaging for Glioma
A clinical trial, sponsored by Susan Chang.
- Terminated
- Registry status
- 2
- Enrollment target
NCT03335280: Clinical Trial study, sponsored by Susan Chang.
NCT03335280 is a clinical trial that was terminated before completion, run by Susan Chang. The registered enrollment target is 2 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03335280 was terminated before completion, sponsored by Susan Chang.
- TERMINATED
- Registry status
- 2 participants
- Enrollment target
Study Summary
This is a prospective, single center, open-label study in adult patients with presumed World Health Organization (WHO) grade 3 or 4 glioma who will be undergoing surgical resection as standard of care. In some cases, patients will have had biopsy. Study participants will undergo 68Ga-citrate Positron Emission Tomography / magnetic resonance (PET/MR) prior to surgery.
Primary Outcome
The location and extent of 68Ga-citrate uptake will be compared to both same day magnetic resonance imaging (MRI) and subsequent pathology. SUVmax will be the outcome of interest and summarized with descriptive measures. SUVmax will be compared via a two-sided two-sample equal-variance t-test between those patients positive for PTEN deletion and those negative for PTEN deletion.
Interventions
- DRUG 68Ga-citrate PET/MR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2019-02-26 |
| Est. Completion | 2020-04-24 |
Why NCT03335280 stopped before completion
NCT03335280 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 2 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which 68Ga-citrate PET/MR is the first listed.
NCT03335280 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03335280 about?
NCT03335280 is a clinical study titled "68Ga-citrate PET/MR Imaging for Glioma". This is a prospective, single center, open-label study in adult patients with presumed World Health Organization (WHO) grade 3 or 4 glioma who will be undergoing surgical resection as standard of care. In some cases, patients will have had biopsy. Study participants will undergo 68Ga-citrate Positro...
What is the current status of trial NCT03335280?
This trial is currently terminated. The enrollment target is 2 participants. The study started on 2019-02-26. Estimated completion is 2020-04-24.
What interventions are being tested in trial NCT03335280?
The interventions under investigation include: 68Ga-citrate PET/MR (DRUG).
Who is sponsoring clinical trial NCT03335280?
This trial is sponsored by Susan Chang, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI